Skip to main content

Table 4 Secondary outcome measures during 6 months Of treatment with cineole or placebo for change of lung function and dyspnea symptoms *

From: Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial

LUNG FUNCTION AND SYMPTOMS PLACEBO CINEOLE  
  BASE LINE 3 MONTHS 6 MONTHS BASE LINE 3 MONTHS 6 MONTHS p-Value
FEV 1 [l] 1.61 ± 0.5 1.62 ± 0.5 1.61 ± 0.5 1.62 ± 0.5 1.67 ± 0.5 1.70 ± 0.6 0.0627
FVC [l] 2.23 ± 0.8 2.25 ± 0.8 2.22 ± 0.7 2.33 ± 0.8 2.36 ± 0.9 2.36 ± 0.9 0.2409
VC [l] 2.81 ± 0.8 2.71 ± 0.7 2.68 ± 0.8 2.80 ± 0.8 2.73 ± 0.8 2.72 ± 0.9 0.2060
Trouble in breathing # 1.8 ± 0.9 2.1 ± 0.9 2.2 ± 1.0 1.9 ± 0.9 2.4 ± 1.0 2.5 ± 1.1 0.0103&
Dyspnea in the morning $ 1.1 ± 0.7 0.9 ± 0.7 0.7 ± 0.7 1.1 ± 0.8 0.7 ± 0.7 0.5 ± 0.6 0.0466&
Dyspnea at rest $ 0.7 ± 0.7 0.4 ± 0.6 0.4 ± 0.6 0.6 ± 0.6 0.3 ± 0.5 0.3 ± 0.5 0.0156&
Dyspnea during exercise $ 2.0 ± 0.6 1.8 ± 0.7 1.7 ± 0.8 2.0 ± 0.6 1.7 ± 0.7 1.5 ± 0.9 0.1252&
  1. * Plus – minus values are means ± SD. Higher scores on the symptoms-sum-score indicate more disease activity.
  2. P-Values are for the comparison of the changes from base line to 6 months between the two groups.
  3. &P-Values for the comparison are calculated by the multiple criteria calculation of 6 visits by Wei-Lachin between the two groups.
  4. # Scores: 0 = no day was good, 1 = 1–3 days were good, 2 = nearly every day was good, 3 = every day was good in a week.
  5. $ Scores: 0 = did not cause any problems, 1 = sometimes caused problems, 2 = caused a lot of problems, 3 = the most important problem the patient had